PNAS£ºÊ×´ÎÀûÓÃCRISPRʵÏÖÌØÊâ¸Éϸ°û³ÉÌå»ùÒòÐÞ¸´
±±¾©ÉúÃü¿ÆÑ§Ñо¿ËùµÄÑо¿ÈËÔ±Ê×´ÎÀûÓÃÌåÍâ³ÉÊìµÄCas9/sgRNAºËÌǵ°°×¸´ºÏÎïÔÚ²¡ÈËÌØÒìÐÔµÄÒþÐÔÓªÑø²»Á¼ÐÔ´óðåÐÔ±íÆ¤ËɽâÖ¢£¨Recessive dystrophic epidermolysis bullosa, RDEB£©Ð¡Êó±íƤ¸Éϸ°ûʵÏÖÁ˳ÉÌå»ùÒòÐÞ¸´£¬´Ó¶øÎªRDEB¼²²¡ÒÔ¼°ÆäËüÒÅ´«ÐÔÆ¤·ô¼²²¡µÄÖÎÓúÌṩÁËȫз½°¸¡£ÕâÒ»Ñо¿³É¹û¹«²¼ÔÚpNASÔÓÖ¾ÉÏ¡£
ÒþÐÔÓªÑø²»Á¼ÐÔ´óðåÐÔ±íÆ¤ËɽâÖ¢ÊÇÓÉÆ¤·ôÖÐVIIÐͽºÔ£¨Collagen VII£©µ°°×¹¦ÄÜÒì³£ÒýÆðµÄÒþÐÔÆ¤·ôÒÅ´«²¡¡£ÔÚÕý³£Æ¤·ôÖУ¬±íƤ½Ç»¯Ï¸°û£¨Keratinocyte£©ÓëÕæÆ¤ÖеijÉÏËάϸ°û(Fibroblast)·ÖÃÚµÄCollagen VIIÊ×ÏÈÐγÉͬԴÈý¾ÛÌ壬Ȼºó×é×°³ÉêÔÏËά£¨anchoring fibrils£©£¬´Ó¶øÊ¹µÃ±íƤÓëÕæÆ¤Àι̽áºÏ¡£ÔÚRDEB²¡ÈËÌåÄÚ£¬Col7a1»ùÒòÖÐһЩͻ±äʹµÃVIIÐͽºÔ¹¦ÄÜÒì³££¬´Ó¶øµ¼ÖÂ±íÆ¤ÓëÕæÆ¤µÄÍÑÀ룬²úÉúѪðå¡£
»ùÒòÖÎÁÆÊÇΨһ¿ÉÒÔ¸ùÖδËÀ༲²¡µÄÖÎÁÆ·½·¨¡£CRISpR/Cas9ϵͳÊÇÒ»ÖÖ¸ßЧµÄ»ùÒò±à¼ÏµÍ³£¬½üÄêÀ´Öð½¥ÓÃÀ´ÖÎÁÆÒ»Ð©ÒÔǰºÁÎÞ¸ùÖη½·¨µÄÒÅ´«¼²²¡¡£µ«£¬¸ßЧµÄÌåÄÚµ¼ÈëCRISpR/Cas9µÄתÔËÏµÍ³Ò»Ö±ÖÆÔ¼×ÅÕâÖÖ¼¼ÊõÏòÁÙ´²µÄÓ¦Óá£
Ϊ̽Ë÷ÀûÓÃCRISpR/Cas9ϵͳʵÏÖ³ÉÌå»ùÒò±à¼´Ó¶øÖÎÓúRDEB¼²²¡£¬±±¾©ÉúÃü¿ÆÑ§Ñо¿Ëù³ÂæÃʵÑéÊÒÑо¿ÈËÔ±Ê×ÏȽ¨Á¢²¡ÈËÌØÒìÐÔµØRDEBСÊóÄ£ÐÍ¡£Í»±ä´¿ºÏÌ壨Col7a1 c.6485G>A mut/mut£©Ð¡ÊóÔÚ³öÉúºó³öÏÖÓ벡ÈËÏàËÆµÄѪðå±íÐÍ¡£¶øÔÓºÏÐÍ£¨Col7a1 c.6485G>A wt/mut£©Ð¡Ê󯤷ôÍêÕû£¬Ã»ÓгöÏÖÈκβ¡Ö¢¡£×éÖ¯ÇÐÆ¬½á¹ûÏÔʾÔÚ³öÏÖѪðåλÖÃµÄÆ¤·ô£¬±íƤÓëÕæÆ¤²ãÏà·ÖÀë¡£¼´Ê¹ÔÚûÓгöÏÖѪðåµÄ±³²¿Æ¤·ôÒÔ¼°Î²°ÍÉÏµÄÆ¤·ô£¬±íƤÓëÕæÆ¤Á¬½ÓËÉÉ¢£¬Ò²³ÊÏÖ³ö±íƤÓëÕæÆ¤·ÖÀëµÄ±íÐÍ¡£Collagen VIIÃâÒßÓ«¹âȾɫ½á¹ûÏÔʾ£¬ÔÚÒ°ÉúÐÍÀÏÊ󯤷ôCollagen VII³ÊÏßÐÔ·Ö²¼ÔÚ±íÆ¤ÓëÕæÆ¤Ö®¼äµÄ»ùµ×²ãλÖ᣶øÔÚÍ»±ä´¿ºÏÌåÖУ¬Collagen VIIµ°°×ÔòÃÖÉ¢·Ö²¼ÔÚ±íÆ¤µÄ»ùµ×²ãϸ°û£¨Basal cells£©ÒÔ¼°¿¿½ü»ùµ×²ãµÄÕæÆ¤²ãϸ°ûÖС£
Ë÷È¡Life Tech CRISpRÔØÌåµÄÏêϸ¼¼Êõ×ÊÁÏ£¬ÇëÌîдÁªÏµ·½Ê½
Collagen VII µ°°×°´ÕÕÆä½á¹¹ÌØÕ÷£¬¿É·ÖΪN¶ËNC1¡¢Î»ÓÚÖв¿µÄÖв¿ÂÝÐý½á¹¹Óò£¨central helical region£©ÒÔ¼°C¶ËNC2½á¹¹Óò¡£ÆäÖÐÖв¿ÂÝÐý½á¹¹ÓòÔÚµ°°×ÖÊһά½á¹¹ÉÏÓÉÐíÐí¶à¶à¡°Gly-X-Y¡±Öظ´ÐòÁй¹³É¡£ÀíÂÛÉÏ£¬½«º¬ÓÐÍ»±äµÄµÚ80λÍâÏÔ×Ó½øÐÐÇгýºó£¬Ö»»áµ¼ÖÂCollagen VII µ°°×ÔÚ³¤¶ÈÉÏÉÔ΢Ëõ¶Ì£¬¶ø²»»á¶ÔÆäµ°°×¹¦ÄÜÔì³ÉÓ°Ï졣ΪÁËÑéÖ¤µÚ80λÍâÏÔ×ÓÇгýÊÇ·ñ°²È«£¬Ñо¿ÈËÔ±ÔÙÒ»´Îͨ¹ýCRISpR/Cas9ϵͳ½éµ¼µÄNHEJϸ°ûÐÞ¸´Í¾¾¶ÖÆ×÷Á˵Ú80λÍâÏÔ×Óת¼ȱʧСÊó£¨Col7a1 ¦¤Exon80£©¡£ÔÓºÏÒÔ¼°´¿ºÍÍ»±äСÊóÓëÒ°ÉúÐÍСÊó±íÐÍÒ»Ö£¬ÐÂÉúÊóÓë³ÉÄêÊó¶¼Ã»ÓÐRDEB¼²²¡µÄѪðå±íÐÍ¡£Collagen VIIµ°°×ÎÞÂÛÊÇÔÚÍ»±äÔÓºÏÌ廹ÊÇ´¿ºÏÌåÖж¼³ÊÏßÐÔ·Ö²¼ÔÚ»ùµ×²ãλÖá£×éÖ¯ÇÐÆ¬Ò²ÏÔʾͻ±äÔÓºÏÌåÓë´¿ºÏÌåСÊ󯤷ô×éÖ¯½á¹¹ÍêÕû£¬±íƤÓëÕæÆ¤Á¬½ÓÍêºÃ¡£Ñо¿ÈËÔ±½ÓÏÂÀ´É¸Ñ¡³öÄܹ»ÌØÒì¡¢¸ßЧµØ½éµ¼µÚ80λÍâÏÔ×ÓÇгýµÄsgRNAs£¬²¢ÔÚÌåÍâ±íƤ¸Éϸ°ûϵÖÐÑéÖ¤ÁËsgRNAÄܹ»³É¹¦½éµ¼µÚ80λÍâÏÔ×ÓÇгý¡£
Ëæºó£¬Ñо¿ÈËÔ±½¨Á¢ÁËͨ¹ýµç»÷½éµ¼µÄCas9/sgRNAºËÌǵ°°×¸´ºÏÎïÆ¤ÄÚµ¼Èëϵͳ¡£ÎªÁË׼ȷ¡¢ÑϽ÷µØÖ¤Ã÷CRISpR/Cas9ϵͳתÔ˵½Æ¤·ôϸ°ûÄÚ²¢ÇÒÄܹ»Õý³£·¢»ÓÆä¹¦ÄÜ£¬Ñо¿ÈËÔ±Óñí´ïCas9µ°°×ÒÔ¼°Á½¸öÌØÒìÐÔʶ±ðFloxλµãµÄsgRNAµÄÖÊÁ£Í¨¹ýµç»÷µÄ·½·¨µ¼ÈëÆ¤·ôϸ°ûÀ´¼¤»îRosa26-stop-tdTomatoСÊóβ²¿Æ¤·ôϸ°û£¬·¢ÏÖ¼¸ºõËùÓеÄRFp+ϸ°û·Ö²¼ÔÚÒÑ·Ö»¯µÄ½ÇÖÊϸ°ûÖС£µ±½«ÖÊÁ£Ìæ»»³ÉCas9/sgRNA Ai14-L/RºËÌǵ°°×¸´ºÏÎïʱ£¬ Cas9/sgRNAºËÌǵ°°×¸´ºÏÎï²»µ«Äܹ»×ªÔ˵½ÒÑ·Ö»¯µÄ½ÇÖÊϸ°ûÖУ¬Í¬Ñù¿ÉÒÔ¸ßЧµÄתÔ˵½»ùµ×²ãϸ°ûÖС£Í¨¹ý³¤Ê±¼äµÄ¸ú×ٹ۲졣Ñо¿ÈËԱ֤ʵRFp+»ùµ×²ãϸ°û²»µ«¿ÉÒÔËæ×Åʱ¼ä½øÐÐÀ©Ôö£¬¶øÇÒ¿ÉÒÔ·Ö»¯³É±íƤ²ãϸ°û¡£
ΪÁËÖ¤Ã÷Cas9/sgRNAºËÌǵ°°×¸´ºÏÎïÔÚСÊóÌåÄÚ¶ÔCol7a1»ùÒò½øÐÐÁËÍâÏÔ×ÓÇгý£¬²¢ÇҺϳÉÁË80λÍâÏÔ×ÓȱʧµÄmRNA£¬Ñо¿ÈËÔ±ÔÚCol7a1 c.6485G>A mut/mut, Rosa26-stop-tdTomato fl/wtСÊóÖУ¬ÀûÓÃCas9/sgRNA£¨sgRNA col7a1-L/R, sgRNA-Ai14-L/R£©ºËÌǵ°°×¸´ºÏÎï½øÐÐCol7a1µÚ80λÍâÏÔ×ÓÇгýͬʱ¼¤»îAi14ϸ°û¡£ÔÚ¸»¼¯RFp+ϸ°ûÖУ¬Ñо¿ÈËÔ±ÔÚСÊóÌåÄڳɹ¦¼ì²âµ½ÁË»ùÒò×éDNAÒÔ¼°mRNA±à¼Ö®ºóµÄ²úÎ²¢ÇÒͨ¹ý²âÐò½øÐÐÁËÑéÖ¤¡£¸üÎªÖØÒªµÄÊÇ£¬Ñо¿ÈËÔ±¶ÔÐÞ¸´ºóµÄСÊ󯤷ôÖÐCollagen VII½øÐÐÁËÃâÒßÓ«¹âȾɫµÄ·ÖÎö¡£Ò»µ©½øÐÐÒ»´ÎƤÄÚ×¢ÉäCas9/sgRNA-col7a1-L/RºËÌǵ°°×¸´ºÏÎï²¢½øÐеç»÷ºó£¬Collagen VIIµ°°×ÔÚ»ùµ×²ã´¦·Ö²¼Ã÷ÏÔÔö¶à¡£ÁíÍ⣬ÔÚ¾¹ý»ùÒòÐÞ¸´ºóµÄcol7a1 c.6485G>A-mut/mutСÊóÖУ¬±íƤÓëÕæÆ¤Õ³¸½±ÈÀý´Ó~30%ÉÏÉýµ½~60%¡£
×ÛÉÏËùÊö£¬Cas9/sgRNAºËÌǵ°°×¸´ºÏÎïÄܹ»Í¨¹ýµç»÷½éµ¼ÌåÄÚCol7a1»ùÒòµÄ±à¼£¬´Ó¶ø£¬»Ö¸´Collagen VIIµ°°×¹¦ÄÜ£¬²¢ÇÒ£¬ÐÞ¸´RDEB±íÐÍ¡£
ÔÎıêÌ⣺
Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model